Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer.
10.3760/cma.j.cn112152-20210226-00173
- VernacularTitle:艾立布林治疗晚期乳腺癌疗效和安全性的多中心真实世界研究
- Author:
Die SANG
1
;
Li Hua SONG
2
;
Li Jun DI
3
;
Ya Lan WANG
4
;
Cai Gang LIU
5
;
Zhong Qing GUO
1
;
Qiu Yue LIU
2
;
Huan WANG
3
;
Shi Yu LI
1
;
Peng YUAN
6
Author Information
1. Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing 100122, China.
2. Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
3. Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
4. Department of Lymphoma and Breast Oncology, Baotou Tumor Hospital, Baotou 014030, China.
5. Department of Cancer, Breast Cancer Center, Shengjing Hospital of China Medical University, Shenyang 110000, China.
6. Special Medical Department, National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Multicenter Study
- Keywords:
Adverse reactions;
Breast neoplasms;
Efficacy;
Eribulin
- MeSH:
Breast Neoplasms/pathology*;
Female;
Furans/adverse effects*;
Humans;
Ketones/adverse effects*;
Paclitaxel/adverse effects*;
Treatment Outcome;
Triple Negative Breast Neoplasms/drug therapy*
- From:
Chinese Journal of Oncology
2022;44(4):364-369
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the efficacy and safety of real-world eribulin in the treatment of metastatic breast cancer. Methods: From December 2019 to December 2020, patients with advanced breast cancer were selected from Beijing Chaoyang District Sanhuan Cancer Hospital, Shandong Cancer Hospital, Peking University Cancer Hospital, Baotou Cancer Hospital, Shengjing Hospital Affiliated to China Medical University, and Cancer Hospital of Chinese Academy of Medical Sciences. Kaplan-Meier method and Log rank test were used for survival analysis, and Cox regression model was used for multivariate analysis. Results: The median progression-free survival (PFS) of 77 patients was 5 months, the objective response rate (ORR) was 33.8%, and the disease control rate (DCR) was 71.4%. The ORR of patients with triple-negative breast cancer was 23.1%, and the DCR was 57.7%; the ORR of patients with Luminal breast cancer was 40.0%, and the DCR was 77.8%; the ORR of patients with HER-2 overexpression breast cancer was 33.3%, and the DCR was 83.3%. ORR of 50.0% and DCR of 66.7% for patients treated with eribulin as first to second line treatment, ORR of 29.4% and DCR of 76.5% for patients treated with third to fourth line and ORR of 28.6% and DCR of 71.4% for patients treated with five to eleven line. The ORR of patients in the eribulin monotherapy group was 40.0% and the DCR was 66.0%; the ORR of patients in the combination chemotherapy or targeted therapy group was 22.2% and the DCR was 81.5%. Patients with a history of treatment with paclitaxel, docetaxel, or albumin paclitaxel during the adjuvant phase or after recurrent metastasis had an ORR of 32.9% and a DCR of 69.9% when treated with eribulin. The treatment efficacy is an independent prognostic factor affecting patient survival (P<0.001). The main adverse reactions in the whole group of patients were Grade Ⅲ-Ⅳ neutrophil decline [29.9% (23/77)], and other adverse reactions were Grade Ⅲ-Ⅳ fatigue [5.2% (4/77)], Grade Ⅲ-Ⅳ peripheral nerve abnormality [2.6% (2/77)] and Grade Ⅲ-Ⅳ alopecia [2.6% (2/77)]. Conclusions: Eribulin still has good antitumor activity against various molecular subtypes of breast cancer and advanced breast cancer that has failed multiple lines of chemotherapy, and the adverse effects can be controlled, so it has a good clinical application value.
